Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/33037
Başlık: | Investigation of new treatment option for hepatocellular carcinoma: A combination of sorafenib with usnic acid |
Yazarlar: | Yurdacan, Beste Eskiler, Gamze Güney Bursa Uludağ Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri/Tıbbi Biyoloji Bölümü. 0000-0002-1619-6680 0000-0002-3820-424X 0000-0002-3316-316X 0000-0002-3316-316X 0000-0001-7904-883X Egeli, Ünal Eryılmaz, Işıl Ezgi Çeçener, Gülşah Tunca, Berrin ABI-6078-2020 AAP-9988-2020 GWV-3548-2022 AAH-1656-2021 AAH-1420-2021 55665145000 57189380840 6508156530 6602965754 |
Anahtar kelimeler: | Combination treatment Hepatocellular carcinoma Sorafenib Usnic acid Antitumor-activity Cancer-cells Inhibition Pathway Gene P16 Pharmacology & pharmacy |
Yayın Tarihi: | Tem-2019 |
Yayıncı: | Oxford University |
Atıf: | Yurdacan, B. vd. (2019). ''Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid''. Journal of Pharmacy and Pharmacology, 71(7), 1119-1132. |
Özet: | Objectives Sorafenib (SOR) is an orally administered molecular targeted agent in the systemic chemotherapy of hepatocellular carcinoma (HCC). However, the partial response of SOR is limited due to its adverse side effect and high heterogeneity and resistant phenotype of HCC. In the current study, we investigated synergistic effects of SOR and usnic acid (UA) on HCC cell lines including HepG2 and SNU-449, and a normal cell line, HUVEC. Methods The antiproliferative and apoptotic effects of combination therapy and SOR alone were analysed by WST-1 and Annexin V analysis, respectively. Furthermore, cell cycle, gene expression analysis of SOR-targeted kinases and acridine orange-ethidium bromide staining were also performed in combined treatments. Key findings Our results demonstrated that SOR and UA combination indicated a strong synergism in HCC cell lines and reduced SOR toxicity in HUVEC cells. Additionally, the combination treatment SOR and UA significantly induced much more apoptotic cell death and G0/G1 arrest through downregulation of SOR-targeted kinases. Conclusions Consequently, SOR and UA combination could be a new therapeutic strategy for HCC treatment. |
URI: | https://doi.org/10.1111/jphp.13097 https://academic.oup.com/jpp/article/71/7/1119/6122173 http://hdl.handle.net/11452/33037 |
ISSN: | 0022-3573 2042-7158 |
Koleksiyonlarda Görünür: | Web of Science |
Bu öğenin dosyaları:
Dosya | Açıklama | Boyut | Biçim | |
---|---|---|---|---|
Egeli_vd_2019.pdf | 3 MB | Adobe PDF | ![]() Göster/Aç |
Bu öğe kapsamında lisanslı Creative Commons License